Lopinavir/Ritonavir Viatris is used in combination with other medicines to treat patients over two years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). Lopinavir/Ritonavir Viatris contains the active substances lopinavir and ritonavir. Lopinavir/Ritonavir Viatris is a ‘generic medicine’. This means that it contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Lopinavir/Ritonavir Viatris is Kaletra. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf).
Therapeutic Indication
### Therapeutic indication Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years. The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.
Therapeutic Area (MeSH)
ATC Code
J05AR10
ATC Item
lopinavir and ritonavir
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
EMA Name
Lopinavir/Ritonavir Mylan
Medicine Name
Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)
Aliases
N/ANo risk management plan link.
